199 related articles for article (PubMed ID: 17768107)
1. Where next with atypical hemolytic uremic syndrome?
Jokiranta TS; Zipfel PF; Fremeaux-Bacchi V; Taylor CM; Goodship TJ; Noris M
Mol Immunol; 2007 Sep; 44(16):3889-900. PubMed ID: 17768107
[TBL] [Abstract][Full Text] [Related]
2. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Hirt-Minkowski P; Dickenmann M; Schifferli JA
Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
[TBL] [Abstract][Full Text] [Related]
3. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
Richards A; Kavanagh D; Atkinson JP
Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
[TBL] [Abstract][Full Text] [Related]
4. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
[TBL] [Abstract][Full Text] [Related]
5. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue.
Atkinson JP; Liszewski MK; Richards A; Kavanagh D; Moulton EA
Ann N Y Acad Sci; 2005 Nov; 1056():144-52. PubMed ID: 16387683
[TBL] [Abstract][Full Text] [Related]
6. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding of pathogenesis of aHUS and HELLP.
Fang CJ; Richards A; Liszewski MK; Kavanagh D; Atkinson JP
Br J Haematol; 2008 Nov; 143(3):336-48. PubMed ID: 18691170
[TBL] [Abstract][Full Text] [Related]
8. [Hemolytic uremic syndrome in adults].
Hertig A; Ridel C; Rondeau E
Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
10. [Hemolytic uremic syndrome].
Rota S; Cravedi P; Remuzzi G; Ruggenenti P
G Ital Nefrol; 2005; 22 Suppl 33():S57-64. PubMed ID: 16419008
[TBL] [Abstract][Full Text] [Related]
11. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
12. Atypical haemolytic uraemic syndrome.
Kavanagh D; Goodship TH; Richards A
Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
[TBL] [Abstract][Full Text] [Related]
13. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
14. Update on evaluating complement in hemolytic uremic syndrome.
Kavanagh D; Goodship TH
Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
[TBL] [Abstract][Full Text] [Related]
15. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
17. Complement in typical hemolytic uremic syndrome.
Orth D; Würzner R
Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
[TBL] [Abstract][Full Text] [Related]
18. Does complement factor B have a role in the pathogenesis of atypical HUS?
Kavanagh D; Kemp EJ; Richards A; Burgess RM; Mayland E; Goodship JA; Goodship TH
Mol Immunol; 2006 Mar; 43(7):856-9. PubMed ID: 16061287
[TBL] [Abstract][Full Text] [Related]
19. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
[TBL] [Abstract][Full Text] [Related]
20. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
